Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
XRAY leans on its Return-to-Growth plan, new distributor wins and AI-enabled launches ??? while forex and Europe demand softness linger.
Zacks
More News
Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership
SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.
Zacks
Hinge Health Expands HingeSelect to Offer End-to-End MSK Surgical Care
HNGE expands HingeSelect to include orthopedic surgery, aiming to deliver coordinated end-to-end MSK care from imaging to post-op recovery.
Zacks
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.
Zacks
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
VEEV's strong Q1, growing Vault CRM migrations and AI expansion support growth, though life sciences CRM market saturation poses risks.
Zacks
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.
Zacks
AMN Expands Language Services Portfolio With Jaide Health Deal
AMN Healthcare acquires Jaide Health to add AI-powered interpretation and translation, widening language access across more healthcare touchpoints.
Zacks
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.
Zacks
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
MMSI leans on therapeutic strength, an oncology acquisition and a new stent launch, but tariffs, OEM weakness and China pressure shadow 2026.
Zacks
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
Natera teams with CytoDyn to track ctDNA in CLOVER Phase 2, using Signatera to map leronlimab response in metastatic colorectal cancer.